Особенности состояния эндотелия при Ph-негативных миелопролиферативных новообразованиях
https://doi.org/10.18699/SSMJ20210603
Аннотация
Тромботические осложнения вносят существенный вклад в тяжесть течения заболевания и смертность при Phнегативных миелопролиферативных новообразованиях (МПН), включая истинную полицитемию, эссенциальную тромбоцитемию и первичный миелофиброз. Сосудистый эндотелий является неотъемлемым компонентом системы гемостаза, нарушение функциональности которого играет важную роль в развитии протромботических состояний. В обзоре приведен анализ имеющихся данных литературы по оценке особенностей эндотелия при Ph-негативных МПН и их выявлению при помощи различных методов. Поиск литературных источников проводили с использованием баз данных PubMed и eLibrary. Анализ результатов исследований с применением различных методов оценки свидетельствует, что для пациентов с Ph-негативными МПН характерны активация, повреждение и, следовательно, дисфункция эндотелия. Ассоциированные с миелопролиферацией нарушения эндотелия отражаются на реализации всех его функций. Эндотелиальная дисфункция является важным патогенетическим звеном развития тромботических осложнений при Ph-негативных МПН.
Об авторе
Н. Е. Корсакова
Российский НИИ гематологии и трансфузиологии ФМБА России
Россия
Россия
Наталья Евгеньевна Корсакова
191024, г. Санкт-Петербург, ул. 2-я Советская, 16
Список литературы
1. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования. М.: Литтерра, 2016. 304 с. Abdulkadyrov K.M., Shuvaev V.A., Martynkevich I.S. Myeloproliferative neoplasms. Moscow: Litterra, 2016. 304 p. [In Russian].
2. Finazzi G., Rambaldi A., Guerini V., Carobbo A., Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2V617F mutation status. Haematologica. 2007;92:135–136. doi: 10.3324/haematol.10634
3. Landolfi R., di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica. 2011;96(2):183–186. doi: 10.3324/haematol.2010.038299
4. Falanga A., Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology. Am. Soc. Hematol. Educ. Program. 2012;2012:571–581. doi: 10.1182/asheducation-2012.1.571
5. Barbui T., Finazzi G., Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13): 2176–2184. doi: 10.1182/blood-2013-03-460154
6. Иванов А.Н., Гречихин А.А., Норкин И.А., Пучиньян Д.М. Методы диагностики эндотелиальной дисфункции. Регионар. кровообращ. и микроциркуляция. 2014;13(4-52):4–11. Ivanov A.N., Grechikhin A.A., Norkin I.A., Puchin’yan D.M. Methods of endothelial dysfunction diagnostics. Regionarnoye krovoobrashcheniye i mikrotsirkulyatsiya = Regional Blood Circulation and Microcirculation. 2014;13(4-52):4–11. [In Russian].
7. Vianello F., Battisti A., Cella G., Marchetti M., Falanga A. Defining the thrombotic risk in patients with myeloproliferative neoplasms. Scientific World Journal. 2011;11:1131–1137. doi: 10.1100/tsw.2011.108
8. Петрищев Н.Н., Васина Л.В., Власов Т.Д., Гавришева Н.А., Меншутина М.А. Типовые формы дисфункции эндотелия. Клин.-лаб. консилиум. 2007;18:31–35. Petrishchev N.N., Vasina L.V., Vlasov T.D., Gavrisheva N.A., Menshutina M.A. Typical forms of endothelium dysfunction. Kliniko-laboratornyy konsilium = Clinical and Laboratory Concilium. 2007;18:31–35. [In Russian].
9. Папаян Л.П., Капустин С.И., Шмелева В.М., Кобилянская В.А. Общие представления о системе гемостаза. Гемофилии. ДВС. Тромбофилии. В кн.: Гематология: национальное руководство. Ред. О.А. Рукавицын. М.: ГЭОТАР-Медиа, 2017;90–133. Papayan L.P., Kapustin S.I., Shmeleva V.M., Kobilyanskaya V.A. General overview of the hemostatic system. Hemophilia. DIC. Thrombophilia. In: Hematology: National Guidelines. Ed. O.A. Rukavitsyn. Moscow: GEOTAR-Media, 2017;90–133. [In Russian].
10. Neunteufl T., Heher S., Stefenelli T., Pabinger I., Gisslinger H. Endothelial dysfunction in patients with polycythaemia vera. Br. J. Haematol. 2001;115(2):354– 359. doi: 10.1046/j.1365-2141.2001.03092.x
11. Reeves B.N., Beckman J.D. Novel pathophysiological mechanisms of thrombosis in myeloproliferative neoplasms. Curr. Hematol. Malig. Rep. 2021;16(3):304–313. doi: 10.1007/s11899-021-00630-8
12. Farina M., Russo D., Hoffman R. The possible role of mutated endothelial cells in myeloproliferative neoplasms. Haematologica. 2021. doi: 10.3324/haematol.2021.278499 [Epub ahead of print]
13. Flammer A.J., Anderson T., Celermajer D.S., Creager M.A., Deanfield J., Ganz P., Hamburg N.M., Lüscher T.F., Shechter M., Taddei S., Vita J.A., Lerman A. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126(6):753–767. doi: 10.1161/CIRCULATIONAHA.112.093245
14. Lessiani G., Dragani A., Falco A., Fioritoni F., Santilli F., Davı` G. Soluble CD40 ligand and endothelial dysfunction in aspirin-treated polycythaemia vera patients. Br. J. Haematol. 2009;145(4):538–540. doi: 10.1111/j.1365-2141.2009.07636.x
15. Yildiz A., Güryildirim M., Pepeler M.S., Yazol M., Oktar S.O., Acar K. Assessment of endothelial dysfunction with flow-mediated dilatation in myeloproliferative disorders. Clin. Appl. Thromb. Hemost. 2018;24(7):1102–1108. doi: 10.1177/1076029618766260
16. Cella G., Marchetti M., Vianello F., Panova-Noeva M., Vignoli A., Russo L., Barbui T., Falanga A. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb. Haemost. 2010;104(1):151–156. doi: 10.1160/TH09-09-0663
17. Piccin A., Steurer M., Feistritzer C., Murphy C., Eakins E., van Schilfgaarde M., Corvetta D., di Pierro A.M., Pusceddu I., Marcheselli L., Gambato R., Langes M., Veneri D., Perbellini O., Pacquola E., Gottardi M., Gherlinzoni F., Mega A., Tauber M., Mazzoleni G., Piva E., Plebani M., Krampera M., Gastl G. Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. Transl. Res. 2017;184:21–34. doi: 10.1016/j.trsl.2017.02.001
18. Cokic V.P., Beleslin-Cokic B.B., Tomic M., Stojilkovic S.S., Noguchi C.T., Schechter A.N. Hydroxyurea induces the eNOScGMP pathway in endothelial cells. Blood. 2006;108(1):184–191. doi: 10.1182/blood-2005-11-4454
19. Friedenberg W.R., Roberts R.C., David D.E. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am. J. Hematol. 1992;40(4):283–289. doi: 10.1002/ajh.2830400408
20. Bellucci S., Ignatova E., Jaillet N., Boffa M.C. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, tPA and vWF. Thromb. Haemost. 1993;70(5):736–742.
21. Falanga A., Marchetti M., Evangelista V., Vignoli A., Licini M., Balicco M., Manarini S., Finazzi G., Cerletti C., Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96(13):4261–4266.
22. Arellano-Rodrigo E., Alvarez-Larraґn A., Reverter J.-C., Colomer D., Villamor N., Bellosillo B., Cervantes F. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden. Am. J. Hematol. 2009;84(2):102–108. doi: 10.1002/ajh.21338
23. Etheridge S.L., Roh M.E., Cosgrove M.E., Sangkhae V., Fox N.E., Chen J., López J.A., Kaushansky K., Hitchcock I.S. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Proc. Natl. Acad. Sci. USA. 2014;111(6):2295–2300. doi: 10.1073/pnas.1312148111
24. Guadall A., Lesteven E., Letort G., Toor S.A., Delord M., Pognant D., Brusson M., Verger E., Maslah N., Giraudier S., Larghero J., Vanneaux V., Chomienne C., El Nemer W., Cassinat B., Kiladjian J.-J. Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features. Thromb. Haemost. 2018;118(9):1586–1599. doi: 10.1055/s-0038-1667015
25. Guy A., Gourdou-Latyszenok V., Le Lay N., Peghaire C., Kilani B., Dias J.V., Duplaa C., Renault M.-A., Denis C., Villeval J.L., Boulaftali Y., Jandrot-Perrus M., Couffinhal T., James C. Vascular endothelial cell expression of JAK2V617F is sufficient to promote a prothrombotic state due to increased P-selectin expression. Haematologica. 2019;104(1):70–81. doi: 10.3324/haematol.2018.195321
26. Mital A., Prejzner W., Bieniaszewska M., Hellmann A. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients. Pol. Arch. Med. Wewn. 2015;125(12):914–920. doi: 10.20452/pamw.3211
27. Mital A., Prejzner W., Hellmann A. Acquired von Willebrand syndrome during the course of myelofibrosis: Analysis of 32 cases. Adv. Clin. Exp. Med. 2015;24(6):1001–1006. doi: 10.17219/acem/52361
28. Mital A., Prejzner W., Swiatkowska-Stodulska R., Hellmann A. Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera – retrospective analysis of 142 consecutive cases. Thromb. Res. 2015;136(4):754–757. doi: 10.1016/j.thromres.2015.07.029
29. Rottenstreich A., Kleinstern G., Krichevsky S., Varon D., Lavie D., Kalish Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur. J. Intern. Med. 2017;41:49–54. doi: 10.1016/j.ejim.2016.11.011
30. Alvarez-Larra´n A., Arellano-Rodrigo E., Reverter J.C., Domingo A., Villamor N., Colomer D., Cervantes F. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann. Hematol. 2008;87(4):269–276. doi: 10.1007/s00277-007-0386-3
31. Musolino C., Alonci A., Bellomo G., Tringali O., Spatari G., Quartarone C., Rizzo V., Calabrò L., Bagnato G., Frisina N. Myeloproliferative disease: Markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology. 2000;4(5):397–402. doi: 10.1080/10245332.1999.11746464
32. Jensen M.K., de Nully Brown P., Thorsen S., Hasselbalch H.C. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am. J. Hematol. 2002;69(3):185–191. doi: 10.1002/ajh.10054
33. Musolino C., Alonci A., Allegra A., Spatari G., Bellomo G., Tringali O., Quartarone C., Squadrito G., Quartarone M. Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications. Am. J. Hematol. 1998;57(2):109–112. doi: 10.1002/(sici)1096-8652(199802)57:2<109::aidajh3>3.0.co;2-#
34. Belotti A., Elli E., Speranza T., Lanzi E., Pioltelli P., Pogliani E. Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146+ immunomagnetic enrichment – Flow cytometry and soluble E-selectin detection. Am. J. Hematol. 2012;87(3):319–320. doi: 10.1002/ajh.22264
35. Robertson B., Urquhart C., Ford I., Townend J., Watson H.G., Vickers M.A., Greaves M. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J. Thromb. Haemost. 2007;5(8):1679–1685. doi: 10.1111/j.1538-7836.2007.02626.x
36. Karakantza M., Giannakoulas N.C., Zikos P., Sakellaropoulos G., Kouraklis A., Aktypi A., Metallinos I.C., Theodori E., Zoumbos N.C., Maniatis A. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int. J. Hematol. 2004;79(3):253–259. doi: 10.1532/IJH97.E0316
37. Bilgir F., Bilgir O., Calan M., Sari F. The levels of adhesion molecules in essential thrombocythemia. Panminerva Med. 2013;55(4):385–390.
38. Musolino C., Calabro’ L., Bellomo G., Martello F., Loteta B., Pezzano C., Rizzo V., Alonci A. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am. J. Hematol. 2002;69(3):159–163. doi: 10.1002/ajh.10020
39. Murphy P., Ahmed N., Hassan H.T. Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera. Leuk. Res. 2002;26(11):1007–1010. doi: 10.1016/s0145-2126(02)00053-x
40. Medinger M., Passweg J. Angiogenesis in myeloproliferative neoplasms, new markers and future directions. Memo. 2014;7:206–210. doi: 10.1007/s12254-014-0142-z
41. Alonci A., Allegra A., Bellomo G., Penna G., D’Angelo A., Quartarone E., Musolino C. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol. Oncol. 2008;26(4):235–239. doi: 10.1002/hon.865
42. Panteli K., Bai M., Hatzimichael E., Zagorianakou N., Agnantis N.J., Bourantas K. Serum levels, and bone marrow immunohistochemical expression of vascular endothelial growth factor in patients with chronic myeloproliferative diseases. Hematology. 2007;12(6):481–486. doi: 10.1080/10245330701554664
43. Trelin´ski J., Wierzbowska A., Krawczyn´ska A., Sakowicz A., Pietrucha T., Smolewski P., Robak T., Chojnowski K. Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. Int. J. Hematol. 2010;91:792–798. doi: 10.1007/s12185-010-0596-7
44. Treliński J., Wierzbowska A., Krawczyńska A., Sakowicz A., Pietrucha T., Smolewski P., Robak T., Chojnowski K. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status. Leuk. Lymphoma. 2010;51(9):1727– 1733. doi: 10.3109/10428194.2010.500435
45. di Raimondo F., Azzaro M.P., Palumbo G.A., Bagnato S., Stagno F., Giustolisi G.M., Cacciola E., Sortino G., Guglielmo P., Giustolisi R. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia. 2001;15(6):976– 980. doi: 10.1038/sj.leu.2402124
46. di Raimondo F., Palumbo G.A., Molica S., Giustolisi R. Angiogenesis in chronic myeloproliferative diseases. Acta Haematol. 2001;106(4):177–183. doi: 10.1159/000046614
47. Gadomska G., Bartoszewska-Kubiak A., Boinska J., Matiakowska K., Ziołkowska K., Haus O., Ros´c´ D. Selected parameters of angiogenesis and the JAK2, CALR, and MPL mutations in patients with essential thrombocythemia. Clin. Appl. Thromb. Hemost. 2018;24(7): 1056–1060. doi: 10.1177/1076029617740222
48. Weltermann A., Wolzt M., Petersmann K., Czerni C., Graselli U., Lechner K., Kyrle P.A. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler. Thromb. Vasc. Biol. 1999;19(7):1757–1760. doi: 10.1161/01.atv.19.7.1757
49. Cacciola R.R., di Francesco E., Giustolisi R., Cacciola E. Elevated serum vascular endothelial growth factor levels in patients with polycythemia vera and thrombotic complications Haematologica. 2002;87(7):774–775.
50. Fadini G.P., Avogaro A. Cell-based methods for ex vivo evaluation of human endothelial biology. Cardiovasc. Res. 2010;87(1):12–21. doi: 10.1093/cvr/cvq119
51. Goon P.K., Boos C.J., Lip G.Y. Circulating endothelial cells: markers of vascular dysfunction. Clin. Lab. 2005;51(9-10):531–538.
52. Torres C., Fonseca A.M., Leander M., Matos R., Morais S., Campos M., Lima M. Circulating endothelial cells in patients with venous thromboembolism and myeloproliferative neoplasms. PLoS One. 2013;8(12):e81574. doi:10.1371/journal.pone.0081574
53. Wu H., Chen H., Hu P.C. Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction. Clin. Lab. 2007;53(5–6):285–295.
54. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., Borrelli G., Rambaldi A., Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310–2313. doi: 10.1182/blood-2006-09-046342
55. Landolfi R., di Gennaro L., Barbui T., de Stefano V., Finazzi G., Marfisi R., Tognoni G., Marchioli R. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446– 2452. doi: 10.1182/blood-2006-08-042515
56. Lowe G.D.O. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J. Thromb. Haemost. 2005;3(8):1618–1627. doi: 10.1111/j.1538-7836.2005.01416.x
57. Zwicker J.I., Liebman H.A., Neuberg D., Lacroix R., Bauer K.A., Furie B.C., Furie B. Tumorderived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer Res. 2009;15(22):6830–6840. doi: 10.1158/1078-0432.CCR-09-0371
58. Trappenburg M.C., van Schilfgaarde M., Marchetti M., Spronk H.M., ten Cate H., Leyte A., Terpstra W.E., Falanga A. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica. 2009;94(7):911– 918. doi: 10.3324/haematol.13774
59. Bar-Natan M., Hoffman R. New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. Haematologica. 2019;104(1):3–6. doi:10.3324/haematol.2018.205989
60. Sozer S., Fiel M.I., Schiano T., Xu M., Mascarenhas J., Hoffman R. The presence of JAK2 V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246– 5249. doi: 10.1182/blood-2008-11-191544
61. Rosti V., Villani L., Riboni R., Poletto V., Bonetti E., Tozzi L., Bergamaschi G., Catarsi P., Dallera E., Novara F., Massa M., Campanelli R., Fois G., Peruzzi B., Lucioni M., Guglielmelli P., Pancrazzi A., Fiandrino G., Zuffardi O., Magrini U., Paulli M., Vannucchi A.M., Barosi G., Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood. 2013;121(2):360–368. doi: 10.1182/blood-2012-01-404889
62. Teofili L., Martini M., Iachininoto M.G., Capodimonti S., Nuzzolo E.R., Torti L., Cenci T., Larocca L.M., Leone G. Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood. 2011;117(9):2700–2707. doi 10.1182/blood-2010-07-297598
63. Castiglione M., Jiang Y.-P., Mazzeo C., Lee S., Chen J.-S., Kaushansky K., Yin W., Lin R.Z., Zheng H., Zhan H. Endothelial JAK2 V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. J. Thromb. Haemost. 2020;18(12):3359–3370. doi: 10.1111/jth.15095
Рецензия
Для цитирования:
Корсакова Н.Е. Особенности состояния эндотелия при Ph-негативных миелопролиферативных новообразованиях. Сибирский научный медицинский журнал. 2021;41(6):30-44. https://doi.org/10.18699/SSMJ20210603
For citation:
Korsakova N.E. Endothelium state in Ph-negative myeloproliferative neoplasms. Сибирский научный медицинский журнал. 2021;41(6):30-44. (In Russ.) https://doi.org/10.18699/SSMJ20210603
Просмотров:
286
Послать статью по эл. почте 